A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D3 regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 10, 2002, Pages 37-40

  Hirata, Michinori ^a   Endo, Koichi ^a   Ohkawa, Hiroyuki ^a   Kumaki, Kenji ^a   Kubodera, Noboru ^a   Slatopolsky, Eduardo ^b   Kurokawa, Kiyoshi ^c   Fukagawa, Masafumi ^d  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcaemic action; OCT; Parathyroid hormone; Secondary hyperparathyroidism; Uraemia; Vitamin D analogue

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 22 OXACALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; DRUG VEHICLE; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL PROTOCOL; CONTROLLED STUDY; DIALYSIS; DISEASE CONTROL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MALE; NEPHRECTOMY; NONHUMAN; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; RAT; UREMIA;

EID: 0036411837     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_10.37     Document Type: Article

References (15)

1. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333: 166-174
2. Slatopolsky E, Weert C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
3. Tsukamoto Y, Nomura M, Takahashi Y et al. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1990; 57: 23-28
4. Abe J, Morikawa M, Miyamoto K et al. Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton. A trial of the development of vitamin D compounds which exhibit potent differentiation-inducing activity without inducing hypercalcemia. FEBS Lett 1987; 226: 58-62
5. Brown AJ, Ritter CR, Finch JL et al. Noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728-732
6. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991; 39: 874-881
7. Kubrusly M, Gagne ER, Urena P et al. Effect of 22-oxacalcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 1993; 44: 551-556
8. Denda M, Finch JL, Brown AJ, Nishii Y, Kubodera N, Slatopolsky E. 1,25-Dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996; 50: 34-39
9. Ichikawa F, Hirata M, Endo K et al. Attenuated up-regulation of vitamin D-dependent calcium-binding proteins by 22-oxa-1,25-dihydroxyvitamin D3 in uremic rats: a possible mechanism for less-calcemic action. Nephrology 1998; 4: 391-395
10. Akizawa T, Suzuki M, Akiba T et al. Clinical effects of maxacalcitriol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001; 38: S147-151
11. Kobayashi T, Tsugawa N, Okano T et al. The binding properties, with blood proteins, and tissue distribution of 22-oxa-1α,25-dihydroxyvitamin D3, a noncalcemic analogue of 1α,25-dihydroxyvitamin D3, in rats. J Biochem 1994; 115:373-380
12. Brown AJ, Finch J, Grieff M et al. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993; 133: 1158-1164
13. Fukuda N, Tanaka H, Tominaga, Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
14. Dusso AS, Negrea L, Gunawardhana S et al. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 1991; 128: 1687-1692
15. Reichel H, Szabo A, Uhl J et al. Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism. Kidney Int 1993; 44: 1259-1265